No Data
Earnings Troubles May Signal Larger Issues for Ningbo Menovo Pharmaceutical (SHSE:603538) Shareholders
Ningbo Menova Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
ningbo menovo pharmaceutical (603538.SH) released its performance for the first three quarters, with a net income of 63.2504 million yuan, a year-on-year increase of 15.97%.
Ningbo Menovo Pharmaceutical (603538.SH) released the third quarter report for 2024, with revenue for the first three quarters at 9.4...
ningbo menovo pharmaceutical (603538.SH): The net income for the first three quarters was 63.2504 million yuan, an increase of 15.97% year-on-year.
On October 29, Glon Hui announced that ningbo menovo pharmaceutical (603538.SH) achieved revenue of 0.949 billion yuan in the first three quarters of 2024, an increase of 2.21% year-on-year; net income attributable to shareholders of the listed company was 63.2504 million yuan, an increase of 15.97% year-on-year; basic earnings per share were 0.29 yuan.
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Menovo Pharmaceutical Signs Cooperation Deal With Nanjing Huawei Pharmaceutical Technology; Shares Down 7%
Ningbo Menovo Pharmaceutical Co., Ltd.'s (SHSE:603538) Price Is Right But Growth Is LackingNo Data
No Data
